US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisition

The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a condition for Aurobindo Pharma to finalize its acquisition of Lannett Company Inc., ensuring no anti-competitive issues arise from the deal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u3jUDq4
via IFTTT